Trailing Twelve Months Revenue Growth: evotec.com (EVO)

Brandmark of evotec.com (EVO)

The partnership strategy with pharma giants to share risks and royalties has a notable impact on the YoY commercial revenue growth for LTM, where the metric stands at 0.30. Evotec SE (EVO) maintains business stability through its own sterile manufacturing plants in the US and Europe, as well as internal automation of laboratory processes that eliminates dependence on third-party vendors.

Evotec SE - EVO Sales Growth YoY (TTM) (period 02/11/2024 - 11/18/2026)
Mass-produced product of evotec.com

The trust of global pharmaceutical giants and the high cost of Evotec SE infrastructure create a powerful defensive barrier, ensuring a steady flow of contracts. Annual sales growth over a rolling four quarters measures the pace of business expansion by filtering short-term volatility through a comparison of TTM revenue with the previous year, allowing investors to assess the company's real expansion beyond market noise.